Abbott Laboratories' business, if not exciting, is resilient and consistent. The company is a leader in multiple markets and has attractive growth avenues. The medical device leader boasts a strong ...

This story originally appeared in New York Focus, a nonprofit news publication investigating power in New York. Sign up for their newsletter here. Julia Calderon’s power used to go out regularly. She ...

The article argues that parents choose schools for reasons beyond test scores, such as safety from bullying. The author contends that such regulations stifle innovation and harm students who struggle ...

A look at a massive tractor that’s built for serious work, towering over everything around it. It’s the kind of machine that makes you wonder who’s brave enough—and skilled enough—to take the wheel.

The Oregon legislature is considering bills to make renewable energy more accessible and the power grid more resilient. One bill would allow homeowners to finance energy-efficient products through ...

Idaho lawmakers are looking to add more accountability measures for virtual schools across the state after a report last year found the state provided little oversight for these schools. Darin Oswald ...

A Holland & Knight litigator is bringing what might be a precedent-setting suit against a medical researcher at MD Anderson Cancer Center in Houston that has long had sovereign immunity from ...

OpenJDK project teams will focus work on features such as value types, code reflection, AOT compilation, and structured concurrency in the coming year. Oracle’s Java team in 2026 will work toward ...

SoFi Technology's appeal among younger customers could present an attractive long-term tailwind. Uber Technologies has yet to tap the full potential of its addressable market. Berkshire Hathaway ...

The announcement of Valve's upcoming Linux-based Steam Machine hit the internet with a largely positive reception — alongside some understandable confusion. Valve's console will purportedly offer up ...

Johnson & Johnson shares surged 46.3% in 2025 to all-time highs above $212 after bottoming near $141 in April. AbbVie yields 6.77% and has grown its dividend at a 10-12% annual rate over the past five ...